Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
ConditionPediatric Anesthesia
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age1-36
SponsorBaylor College of Medicine
About this trial
The purpose of this protocol is to determine the effect of two clinically applicable Dexmedetomidine dosages (0.5mcg/kg and 1mcg/kg) on the minimum alveolar concentration (MAC) of Sevoflurane in children between the age ranges of: 1-6 months; 6-12 months of age and 12 months-36 months years of age.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
Interstitial lung disease, chest wall disease, or bronchospastic disease with no flare-ups in the past 2 weeks of presentation
History of difficult intubation or ventilation
Airway malformation
Congenital heart disease
Trial design
Design model
Single group
Treatments tested in this trial
Dexmedetomidine
DrugDexmedetomidine 9 arms
Treatment groups
180 Participants
are divided into 9 treatment groups9
Treatment groupsSee each treatment group below.
Group A: Dexmedetomidine 0.5 mcg/kg 1-6 monthsActive comparator 1 intervention
Group B: Dexmedetomidine 1 mcg/kg 1-6 monthsActive comparator 1 intervention
Group C: Dexmedetomidine 0.5 mcg/kg 6-12 monthsActive comparator 1 intervention
Group D: Dexmedetomidine 1 mcg/kg 6-12 monthsActive comparator 1 intervention
Group E: Placebo 6-12 monthsPlacebo comparator 1 intervention
Group F: Dexmedetomidine 0.5 mcg/kg 1-3 yearsActive comparator 1 intervention
Group G: Dexmedetomidine 1 mcg/kg 1-3 yearsActive comparator 1 intervention
Group H: Placebo 1-3 yearsPlacebo comparator 1 intervention
Group I: Placebo 1-6 monthsPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
Movement
The study is completed after assessment of patient movement with skin incision
Time frame
Immediately following skin incisionSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov